Dualyx
Dualyx aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company is developing the pipeline together with our academic and industry partners such as Wurzburg University, argenx, KU Leuven and VIB.
Press releases
Press
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates
Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with support from existing investors
Bernard Coulie appointed as Independent Chairman with immediate effect
May 15, 2023, Ghent, Belgium – Dualyx NV, a Ghent based biotech developing next generation immune modulators, today announces that it has
Info & Contact
- E–Mail:
- wverhoeven@dualyx.com
- Web:
- www.dualyx.com
Address
Technologiepark 94
Building 2, Unit 22 (2nd floor)
9052 Zwijnaarde
Building 2, Unit 22 (2nd floor)
9052 Zwijnaarde